On August 23, 2022, the Federal Court issued its public judgment and reasons in two actions under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (the “Regulations”) ...

With respect to tolerability concerns with the recommended paliperidone palmitate initiation dosing, this study did not reveal unexpected adverse events or high rates of specific adverse events in the ...